Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Fluicell logo — Making tissue therapeutics possible to defeat serious diseas...

Fluicell

Making tissue therapeutics possible to defeat serious disease

Founded 2012 Sweden Sweden 16 employees Post-IPO Equity Total: $4.00M Biotechnology, Health Care +1

General Information

Company Name Fluicell
Founded Year 2012
Location Sweden Sweden
Founders / Decision Makers
Team member
Employees 16
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Fluicell. To contact Fluicell, visit fluicell.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Fluicell compare?

A PDF of Fluicell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Fluicell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Fluicell

Fluicell is a Swedish biotechnology startup dedicated to revolutionizing disease treatment through innovative tissue solutions for regenerative medicine and drug screening. The company's groundbreaking Nexocyte platform, developed over two decades of disruptive R&D, introduces novel approaches to combat serious diseases by leveraging precision-engineered biological tissues. These transplantable tissues hold promise in addressing irreparable tissue damage associated with cardiac, pulmonary, metabolic, kidney, and other ailments, with a primary focus on developing solutions for type 1 diabetes. In addition to its therapeutic pursuits, Fluicell collaborates with leading partners to enhance drug-screening capabilities, aiming to facilitate the development of transformative medications. The company secured a kr4.00M Post-IPO Equity investment on 16 October 2020, with support from Pensys, Johan Stein, and Strategic Wisdom Nordic. Fluicell's innovative approach and potential to address unmet medical needs position it as a noteworthy player in the biotechnology, healthcare, and pharmaceutical industries.

Business keywords: Regenerative Medicine, Drug Screening, Tissue Therapeutics, Bioprinting, Microfluidics, Biomedicine, Single-Cell Biology, Single-Cell Pharmacology, Cell Therapy, Diabetes, Precision Engineering, Transplantable Tissues, Patent-Protected R&D

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity kr4.00M 3
Pensys, Johan Stein +1
16 Oct 2020
Seed Round Undisclosed 1
Almi Invest
Almi Invest
01 Jan 2013

Fluicell Alternatives & Competitors

View All Alternatives
Fluicell vs
Satellite Bio
Satellite Bio United States

Tackling some of humankind’s most elusive diseases with Tissue Therapeutics, a new category of regen...

Series A
24 employees
Biotechnology, Pharmaceutical
Fluicell vs
Poietis
Poietis France

Make tissues real

Seed
15 employees
Biotechnology, Pharmaceutical
Fluicell vs
ClexBio
ClexBio United States

Technology should enable biology, not replace it.

9 employees
Biotechnology, Health Care
View all alternatives

FAQ About Fluicell

Making tissue therapeutics possible to defeat serious disease
Fluicell was founded in 2012.
Fluicell is headquartered in Sweden.
Fluicell operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Regenerative Medicine, Drug Screening, Tissue Therapeutics and Bioprinting.
Fluicell has approximately 16 employees.
Fluicell has completed 2 funding rounds, raising a total of $4.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Fluicell include Satellite Bio, Poietis, ClexBio, Cellapeutics bio, PrimeCell Bioscience, a.s.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Fluicell and Satellite Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Fluicell, https://bouncewatch.com/company/fluicell, updated 30 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes